GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands

GlaxoSmithKline, 03/16/2012

GSK announced its intention to divest non–core Consumer Healthcare OTC products predominantly in the United States and Europe with aggregate sales of approximately £500 million. The proposed divestment is designed to realise value for shareholders and simplify GSK's Consumer Healthcare business by enabling it to focus on priority brands and markets.

Print Article Summary Cat 2 CME Report